Cell and Gene Commercialization

  1. Discover The Path To Oncology Success 8/22/2025

    The oncology landscape is brimming with innovative therapies and new treatment approaches. Successful commercialization requires a well-orchestrated strategy to bring these complex products to market.

  2. Don't Let Distribution Derail Your CGT Launch 8/7/2025

    Overcoming distribution challenges is critical for the success of cell and gene therapies. Learn how to build a flexible, robust strategy to optimize patient access.

  3. The Building Blocks Of A Robust Analytical Assay 8/1/2025

    Analytical assays aren't just important for quality control. Regulators expect them. These tips will help if you're just starting to build your analytical package.

  4. Rethinking Partnerships In Cell & Gene Therapy 7/30/2025

    Discover how a unique partnership model helps cell and gene therapy developers accelerate progress, reduce risk, and bring transformative therapies to market faster.

  5. Navigating The Complexities Of NK Cell Therapy Development 7/30/2025

    Deloitte's Amit Agarwal and Ashraf Husain share expert insights on how NK cell therapy developers can overcome manufacturing, supply chain, and commercialization challenges to successfully scale these promising therapies.

  6. Optimizing Commercial Distribution As You Prepare To Launch Your CGT 7/29/2025

    An effective commercial distribution strategy is crucial for new cell and gene therapies, helping manufacturers navigate challenges and ensure patient access.

  7. Strategies For Optimizing iPSC Cryopreservation, Storage, And Post-Thaw Quality 7/29/2025

    Developing iPSC therapies demands meticulous cryopreservation, smart automation, and risk-based post-thaw quality control to bridge lab development with cGMP manufacturing. The sensitivity of iPSCs requires tailored protocols and a deep understanding of cell behavior under scaled conditions, ensuring consistent, viable products.

  8. Innovation That Is Evolving The CGT Landscape In 2025 7/28/2025

    Uncover how cell and gene therapy leaders are adapting to funding pressures, regulatory shifts, and global complexity by prioritizing scalability and strategic partnerships for long-term success.

  9. How Smart Planning Helps CGT Scale Further, Faster 7/25/2025

    Henrik Anderson, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, explores how early planning, automation, and economic discipline can help scale the impact of cell therapies.

  10. Navigating The CGT Supply Chain: Key Logistical Challenges And Solutions 7/16/2025

    Commercializing cell and gene therapies requires overcoming complex logistical hurdles. Customized strategies for temperature control, compliance, and end-to-end delivery are crucial to prevent supply chain issues.